Application of mesenchymal stem cells in preparation of medicine for treating rheumatoid arthritis

Abstract

The invention discloses an application of mesenchymal stem cells in preparation of a medicine for treating rheumatoid arthritis. The mesenchymal stem cells are umbilical cord mesenchymal stem cells, and the medicine also comprises cervus and cucumis polypeptide and tanshinone IIA sodium sulfonate injection liquid. The cervus and cucumis polypeptide LG has the effects of tonifying the kidney, strengthening the bone, removing stasis and stagnation, eliminating dampness and relieving pain; the tanshinone IIA sodium sulfonate injection liquid DS is a fat-soluble effective active ingredient extracted from radix salviae miltiorrhizae, and has the effects of promoting blood circulation to arrest pain, cooling blood and diminishing swelling. The kidney-tonifying and blood-activating traditional Chinese medicine injection liquid LG+DS is adopted for early intervention and can be combined with the UC-MSC for treating the RA, and a result shows that the curative effect of the UC-MSC in treating the RA can be enhanced.

Description

technical field [0001] The invention belongs to the field of rheumatism treatment, and in particular relates to the application of mesenchymal stem cells in the preparation of medicines for treating rheumatoid arthritis. Background technique [0002] Rheumatoid arthritis (RA) is a chronic, systemic autoimmune disease with erosive symmetric polyarthritis as the main clinical manifestation and a high disability rate. RA is distributed globally and is one of the main causes of human loss of labor force and disability. The prevalence of RA in my country is about 0.32%-0.36%. It can occur at any age, 80% of the cases are between 35 and 50 years old, and the number of female patients is about 3 times that of males. The clinical manifestations are symmetrical and persistent polyarthritis mainly involving small joints such as hands and wrists. The basic pathological changes of RA are synovitis and vasculitis. Synovitis is the basis of joint manifestations, and the gradual destruc...

AI Technical Summary

Problems solved by technology

[0004] For a long time, rheumatologists have designed many paradigms for the treatment of rheumatoid, but none of them can completely and effectively control this kind of disease

Traditionally, non-steroidal anti-inflammatory drugs and slow-acting anti-rheumatic drugs are mainly used, but the recurrence rate of the disease is high, the side effects are obvious, and the progress of the disease cannot be changed; in recent years, biological treatment methods targeting cytokines have been developed. However, the use of biological agents is likely to increase the occurrence of various postoperative infections, has no obvious repair ability to damaged joints, and is expensive, which limits its clinical use.

Images